These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 14669348)

  • 1. Plasma matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 as biomarkers of ulcerative colitis activity.
    Wiercinska-Drapalo A; Jaroszewicz J; Flisiak R; Prokopowicz D
    World J Gastroenterol; 2003 Dec; 9(12):2843-5. PubMed ID: 14669348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis.
    Wang YD; Tan XY; Zhang K
    Mediators Inflamm; 2009; 2009():275072. PubMed ID: 19911067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1.
    Flisiak I; Myśliwiec H; Chodynicka B
    J Eur Acad Dermatol Venereol; 2005 Jul; 19(4):418-21. PubMed ID: 15987285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
    Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
    Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imbalance of tissue inhibitors of metalloproteinases (TIMP) - 1 and - 4 serum levels, in patients with inflammatory bowel disease.
    Kapsoritakis AN; Kapsoritaki AI; Davidi IP; Lotis VD; Manolakis AC; Mylonis PI; Theodoridou AT; Germenis AE; Potamianos SP
    BMC Gastroenterol; 2008 Nov; 8():55. PubMed ID: 19036126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of lamivudine treatment on plasma levels of transforming growth factor beta1, tissue inhibitor of metalloproteinases-1 and metalloproteinase-1 in patients with chronic hepatitis B.
    Flisiak R; Al-Kadasi H; Jaroszewicz J; Prokopowicz D; Flisiak I
    World J Gastroenterol; 2004 Sep; 10(18):2661-5. PubMed ID: 15309715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis.
    Wang YD; Yan PY
    World J Gastroenterol; 2006 Oct; 12(37):6050-3. PubMed ID: 17009408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pegylated interferon alpha 2b plus ribavirin treatment on plasma transforming growth factor-beta1, metalloproteinase-1, and tissue metalloproteinase inhibitor-1 in patients with chronic hepatitis C.
    Flisiak R; Jaroszewicz J; Lapinski TW; Flisiak I; Prokopowiczi D
    World J Gastroenterol; 2005 Nov; 11(43):6833-8. PubMed ID: 16425392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma transforming growth factor beta1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B.
    Flisiak R; Jaroszewicz J; Lapiński TW; Flisiak I; Rogalska M; Prokopowicz D
    Regul Pept; 2005 Nov; 131(1-3):54-8. PubMed ID: 16081167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
    Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
    J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity.
    Toubi E; Kessel A; Grushko G; Sabo E; Rozenbaum M; Rosner I
    Clin Exp Rheumatol; 2002; 20(2):221-4. PubMed ID: 12051403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Cyclophilin A Correlates with Increased Tissue MMP-9 in Patients with Ulcerative Colitis, but Not with Crohn's Disease.
    Piechota-Polanczyk A; Włodarczyk M; Sobolewska-Włodarczyk A; Jonakowski M; Pilarczyk A; Stec-Michalska K; Wiśniewska-Jarosińska M; Fichna J
    Dig Dis Sci; 2017 Jun; 62(6):1511-1517. PubMed ID: 28391416
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Matrix metalloproteinases-1, -13 and their tissue inhibitor-1 in endocrine ophthalmopathy].
    Taskina ES; Kharintseva SV
    Probl Endokrinol (Mosk); 2019 May; 65(1):10-18. PubMed ID: 31091046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity.
    Chen CH; Lin KC; Yu DT; Yang C; Huang F; Chen HA; Liang TH; Liao HT; Tsai CY; Wei JC; Chou CT
    Rheumatology (Oxford); 2006 Apr; 45(4):414-20. PubMed ID: 16287916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous up-regulation of matrix metalloproteinases 1, 2, 3, 7, 8, 9 and tissue inhibitors of metalloproteinases 1, 4 in serum of patients with chronic obstructive pulmonary disease.
    Navratilova Z; Zatloukal J; Kriegova E; Kolek V; Petrek M
    Respirology; 2012 Aug; 17(6):1006-12. PubMed ID: 22591289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in sera and tissue of patients with Dupuytren's disease.
    Ulrich D; Hrynyschyn K; Pallua N
    Plast Reconstr Surg; 2003 Oct; 112(5):1279-86. PubMed ID: 14504511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis.
    Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
    J Rheumatol; 2004 Feb; 31(2):238-42. PubMed ID: 14760791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum MMPs 7-9 and their inhibitors during glucocorticoid and anti-TNF-α therapy in pediatric inflammatory bowel disease.
    Mäkitalo L; Rintamäki H; Tervahartiala T; Sorsa T; Kolho KL
    Scand J Gastroenterol; 2012 Jul; 47(7):785-94. PubMed ID: 22519363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.